Loading...
XSHE
300255
Market cap3.01bUSD
Oct 09, Last price  
22.15CNY
1D
1.19%
1Q
-15.91%
Jan 2017
180.38%
IPO
429.90%
Name

Hebei Changshan Biochemical Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XSHE:300255 chart
P/E
—
P/S
23.26
EPS
—
Div yield, %
—
Shrs. gr., 5y
-0.03%
Rev. gr., 5y
-18.02%
Revenues
875m
-15.10%
110,840,402253,753,457466,717,967423,479,330572,499,692704,542,401811,284,569915,987,2291,118,414,4301,420,161,4481,652,633,9202,071,479,8092,363,785,8542,968,050,8422,336,229,8371,410,439,6481,030,810,532875,132,346
Net income
-358m
L+43.46%
9,283,26936,365,48660,190,52670,799,65699,088,101115,182,923133,732,533156,297,279175,487,229196,919,216139,987,097225,285,380252,842,319233,573,84417,513,467-1,240,210,952-249,477,721-357,895,551
CFO
56m
-0.95%
-30,826,60424,210,52129,245,67417,041,533-70,620,873-15,244,396-84,967,293-38,139,133171,959,738162,275,728292,806,829-58,127,157-183,581,1742,871,4983,125,50333,725,97956,218,17055,682,878
Dividend
Jun 27, 20230.005 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. operates within China, focusing on the entire lifecycle of heparin-based pharmaceuticals – from their initial research and development to manufacturing and sales. Their products are primarily utilized for the treatment of cardiovascular and cerebrovascular diseases. The company offers a broad range of heparin compounds, including crude heparin sodium and refined heparin sodium raw materials. Their portfolio also features a variety of injectable heparin preparations, such as standard heparin sodium injections. Furthermore, they produce both the raw materials and finished injectable forms for several low molecular weight heparins, specifically low molecular weight heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium. Established in the year 2000, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is headquartered in Shijiazhuang, China.

Key people

Jie Gao
Vice Chairman of the Board · since 2024
Xiaohua Yue
Chief Financial Officer, Deputy General Manager · since 2023
Wei Zhang
Chief Financial Officer, Secretary of the Board, Deputy General Manager · since 2011
Guohong An
Deputy General Manager · since 2021
Yanlu Chang
Deputy General Manager · since 2024
Zhongying Liu
Deputy General Manager, Secretary of the Board · since 2021
Xinjun Zhang
Deputy General Manager · since 2024
Qing Zhang
Deputy General Manager · since 2020
Tao Zhang
Deputy General Manager · since 2024
Xiaodong Gao
Chairman of the Board, General Manager · since 2024
Zhenggang Qie
Deputy General Manager, Director · since 2023
Yunxia Sun
Deputy General Manager, Director · since 2021
Deying Cao
Independent Director · since 2021
Xiangjun Wang
Independent Director · since 2021
IPO date
Aug 19, 2011
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
中国(河北)自由贸易试验区正定片区正定县高新技术产业开发区南区梦龙街71号
石家庄市, HE 050000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT